Volume 6.45 | Nov 20

Mammary Cell News 6.45 November 20, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
​BRMS1L Suppresses Breast Cancer Metastasis by Inducing Epigenetic Silence of ​FZD10
Researchers show that reduced breast cancer metastasis suppressor 1 like (​BRMS1L) in breast cancer tissues is associated with metastasis and poor patient survival. Functionally, ​BRMS1L inhibits breast cancer cells migration and invasion by inhibiting epithelial-mesenchymal transition. [Nat Commun] Abstract
MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

In Vitro and In Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer
Most compounds are more cytotoxic to a number of human cancer cell lines than cisplatin. Scientists indicated that the cell death type for these compounds is mainly through canonical or caspase-dependent apoptosis, non-dependent on p53, and that the compounds do not interact with DNA or inhibit protease cathepsin B. [J Med Chem] Abstract

2-(4-Hydroxy-3-Methoxyphenyl)-Benzothiazole Suppresses Tumor Progression and Metastatic Potential of Breast Cancer Cells by Inducing Ubiquitin Ligase CHIP
Scientists show that a novel agent, 2-(4-hydroxy-3-methoxyphenyl)-benzothiazole, has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. [Sci Rep] Full Article

Elevated 14,15- Epoxyeicosatrienoic Acid by Increasing of Cytochrome P450 2C8, 2C9 and 2J2 and Decreasing of Soluble Epoxide Hydrolase Associated with Aggressiveness of Human Breast Cancer
The level of 14,15-epoxyeicosatrienoic acid (EET)/14,15-DHET in breast cancer patients was detected by ELISA; the expression and distribution of CYP2C8, 2C9, 2J2 and soluble epoxide hydrolase was determined by quantitative RT-PCR and immunohistochemical staining; and cell proliferation and migration was analyzed by MTT and transwell assays, respectively. [BMC Cancer] Abstract | Full Article

miR-429 Inhibits Migration and Invasion of Breast Cancer Cells In Vitro
Scientists established an in vivo bone metastasis model of breast cancer by injecting MDA-MB-231 cells into the left ventricle of nude mice, and then screened the differentially expressed microRNAs (miRNAs) between parental and bone-metastatic MDA-MB-231 cells using miRNA array. [Int J Oncol] Abstract

Cotylenin A and Arsenic Trioxide Cooperatively Suppress Cell Proliferation and Cell Invasion Activity in Human Breast Cancer Cells
Scientists found that cotylenin A, a plant growth regulator and a potent inducer of differentiation in myeloid leukemia cells, significantly potentiated both arsenic trioxide (ATO)-induced inhibition of cell growth in a liquid culture, and ATO-induced inhibition of anchorage-independent growth in a semi-solid culture in human breast cancer MCF-7 and MDA-MB-231 cells. [Int J Oncol] Abstract

The Role of NOS-Mediated ROS Accumulation in an Early Phase Cu-Induced Acute Cytotoxicity in MCF-7 Cells
Researchers provide data showing that high level of CuCl2 could rapidly decrease the nitric oxide production with the release of Ca2+ and Zn2+, and then modulate the transcriptional and translational expression of nitric oxide synthases in MCF-7 cells. [Biometals] Abstract

Ionizing Radiation Sensitizes Breast Cancer Cells to Bcl-2 Inhibitor, ABT-737, through Regulating Mcl-1
Researchers demonstrate that the combination of ABT-737 and radiation-induced apoptosis had an inhibitory effect on breast cancer cell proliferation. However, treatment with ABT-737 resulted in elevated myeloid cell leukemia 1 (Mcl-1) in breast cancer cell lines. [Radiat Res] Abstract


Anti-Proliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Pre-Surgical Randomized MAPLE Trial (CRUK E/06/039)
Women with primary breast cancers were randomized to 10-14 days of pre-operative lapatinib or placebo in a multicenter Phase II trial. Biopsies pre-/post-treatment were analyzed for Ki67, apoptosis, HER2, EGFR, ER, PgR, pAKT, pERK, & stathmin by IHC. [Cancer Res] Abstract

Zoledronic Acid Combined with Adjuvant Endocrine Therapy of Tamoxifen versus Anastrozol plus Ovarian Function Suppression in Premenopausal Early Breast Cancer: Final Analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Zoledronic acid plus adjuvant endocrine therapy significantly improved disease-free survival at 48 and 62 months’ follow-up in the ABCSG-12 trial. The authors present efficacy results of a final additional analysis after 94.4 months. [Ann Oncol] Abstract

Subcutaneous versus Intravenous Formulation of Trastuzumab for HER2-Positive Early Breast Cancer: Updated Results from the Phase III HannaH Study
Patients were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with three-weekly subcutaneous trastuzumab or the standard weight-based IV method. Following surgery, patients continued trastuzumab treatment to complete one year of therapy. [Ann Oncol] Abstract

Dose-Dense Paclitaxel versus Docetaxel following FEC as Adjuvant Chemotherapy in Axillary Node-Positive Early Breast Cancer: A Multicenter Randomized Study of the Hellenic Oncology Research Group (HORG)
Scientists conducted a randomized study to compare the efficacy of dose-dense paclitaxel versus docetaxel following 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) as adjuvant chemotherapy in women with node-positive early breast cancer. [Breast Cancer Res Treat] Abstract

Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture FREE Protocols
Local Therapy for Breast Cancer in the Molecular Era: Relevant or Relic?
Local therapy is an essential component of breast cancer treatment. Yet, based on clinical trial results dating from the 1980s, the magnitude of local therapy interventions has been decreasing. Now, with the emergence of tailored systemic therapies, their increasing use in the neoadjuvant setting, and their high rates of pathologic complete response, the relevance of local therapy is being questioned. [Oncology] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701), an Advanced Multi-Targeted Kinase Inhibitor
Deciphera Pharmaceuticals announced the presentation of preclinical data which demonstrated that altiratinib (DCC-2701) provided balanced inhibition of MET, TRK, TIE2 and VEGFR2 kinases. [Press release from Deciphera Pharmaceuticals, LLC. discussing research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona] Press Release

Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-Deficient Cancer Model
Nektar Therapeutics announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. [Press release from Nektar Therapeutics discussing research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
Polaris Group Announces Treatment of First Patient in Phase I Study of ADI-PEG 20 Plus Doxorubicin in HER2 Negative Breast Cancer
Polaris Group announced that the first patient has been dosed in its Phase I trial of ADI-PEG 20 in combination with doxorubicin for the treatment of HER2 negative metastatic breast cancer. [Polaris Group (PR Newswire Association LLC)] Press Release

Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Puma Biotechnology, Inc. announced top line results from a Phase II clinical trial of Puma’s investigational drug PB272 for the treatment of first-line HER2-positive locally recurrent or metastatic breast cancer. [Puma Biotechnology, Inc.] Press Release

Collaboration with TapImmune to Advance Targeted Breast & Ovarian Cancer Vaccines into Phase II Clinical Trials
The Vaccine & Gene Therapy Institute of Florida announced a new collaborative research agreement with TapImmune, Inc. forming a partnership to advance TapImmune’s proprietary targeted cancer vaccines into mid-stage Phase II human clinical trials for the treatment of breast and ovarian cancers. [The Vaccine & Gene Therapy Institute of Florida] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2014 World Cancer Congress
December 3-6, 2014
Melbourne, Australia

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

NEW Associate Professor – Physiology (University of Bergen)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Professor – Breast/Abdominal Surgery or Gynecology (Fudan University Shanghai Cancer Center)

Postdoctoral Position – Protein-Protein Interactions in Leukemia and Breast Cancer (University of Dundee)

PhD Position – Protein Interactions in Cancer Regulation (University of East Anglia)

Postdoctoral Fellow – Breast Cancer (University of Texas Health Science Center at San Antonio)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us